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Abstract
Objective
Ischaemia/reperfusion-injury degrades endothelial glycocalyx. Graft glycocalyx degradation
was studied in human liver transplantation.
Methods
To assess changes within the graft, blood was drawn from portal and hepatic veins in addi-
tion to systemic samples in 10 patients. Plasma syndecan-1, heparan sulfate and chondroi-
tin sulfate, were measured with enzyme-linked immunosorbent assay.
Results
During reperfusion, syndecan-1 levels were higher in graft caval effluent [3118 (934–6141)
ng/ml, P = 0.005] than in portal venous blood [101 (75–121) ng/ml], indicating syndecan-1
release from the graft. Concomitantly, heparan sulfate levels were lower in graft caval efflu-
ent [96 (32–129) ng/ml, P = 0.037] than in portal venous blood [112 (98–128) ng/ml], indicat-
ing heparan sulfate uptake within the graft. Chondroitin sulfate levels were equal in portal
and hepatic venous blood. After reperfusion arterial syndecan-1 levels increased 17-fold
(P < 0.001) and heparan sulfate decreased to a third (P < 0.001) towards the end of surgery.
Conclusion
Syndecan-1 washout from the liver indicates extensive glycocalyx degradation within the
graft during reperfusion. Surprisingly, heparan sulfate was taken up by the graft during
reperfusion. Corroborating previous experimental reports, this suggests that endogenous
heparan sulfate might be utilized within the graft in the repair of damaged glycocalyx.
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However, we have removed some of the data on
patient characteristics from the data file. The data
removed are age and sex of the participants and
also all data on the dates of the surgery, hospital
stay and complications. We have done so to
ensure, that none of the patient could be identified
based on public data. This was necessary because
liver transplantation surgeries are performed only
in one single center in Finland. Also, the number of
Introduction
Glycocalyx is a layer of interacting proteoglycans, glycosaminoglycans and glycoproteins cov-
ering the luminal endothelial surface. It serves to sustains microvascular homeostasis and
integrity. Intact glycocalyx regulates vascular tone and permeability, and inhibits blood coagu-
lation. Glycocalyx also appears to control inflammatory responses as it regulates endothelial
adhesion and transmigration of leukocytes and retains cytokines and chemokines within its
heparan sulfate mesh [1,2].
Glycocalyx degradation occurs under pathophysiologic inflammatory conditions such as
sepsis [3], trauma [4], and ischemia/reperfusion (IR) -injury [5–7]. IR-injury is inherent to
liver transplantation. Graft preservation (cold ischemia) primes and activates Kupffer cells and
sinusoidal endothelial cells to release reactive oxygen species (ROS) and inflammatory media-
tors and to express tissue factor upon reperfusion, resulting in direct cytotoxic effects, neutro-
phil recruitment into the liver, and local thrombin generation and intravascular coagulation
[8]. Glycocalyx on the sinusoidal endothelium may be damaged not only by ROS, but also by
matrix metalloproteinases (MMP), neutrophil-derived elastase and thrombin [1]. The altered
glycocalyx structure and function may further exacerbate liver IR-injury by inducing sinusoi-
dal vasoconstriction and tissue edema, by accelerating intravascular thrombosis, and by acti-
vating and recruiting innate immune cells to the graft [1,2,9].
Although elevated levels of heparan sulfate [2] and syndecan-1 [10], the biomarkers of gly-
cocalyx degradation [11], have been reported in the systemic circulation both in clinical liver
surgery with hepatoduodenal ligament clamping [2] and in liver transplantation in cirrhotic
patients [10], neither of these studies addressed the potential IR-injury induced glycocalyx deg-
radation within the liver.
We hypothesized that glycocalyx degradation occurs within the liver graft during reperfu-
sion, and therefore studied plasma proteoglycan (syndecan-1) and glycosaminoglycan
(heparan sulfate, chondroitin sulfate) kinetics across the liver graft in human liver transplanta-
tion. To this end, blood samples were obtained both from the portal vein (ingoing blood) and
hepatic vein (outcoming blood) during and after liver graft reperfusion. As the aim of this
study was to investigate the effects of IR-injury on the hepatic glycocalyx, we sought to elimi-
nate the effects of end-stage liver disease on glycocalyx [10,12] by enrolling only patients
undergoing preemptive liver transplantation for primary sclerosing cholangitis (PSC) [13,14]
without cirrhosis and thus having normal liver function preoperatively.
Materials and methods
Patients
The study protocol was approved by the ethics committee in Helsinki University Hospital
(Dnro 156/13/03/02/2014). After written informed consent, 10 PSC-patients undergoing
orthotopic liver transplantation participated in the study (Table 1). All patients had a moderate
suspicion of cholangiocarcinoma in their brush-cytology samples retrieved with endoscopic
retrograde cholangiography (ERC). In addition, local progression of bile duct strictures sup-
ported the suspicion of cancer. Thus, the transplantation was performed to prevent dysplastic
bile duct lesions from proceeding to invasive carcinoma. One patient had recurrent cholangitis
with exacerbation prior to transplantation and thus higher bilirubin level that was reflected in
higher Model for End-stage Liver Disease (MELD)- and Mayo risk scores. Of the 10 patients, 7
had also inflammatory bowel disease (6 ulcerating colitis, 1 Crohn’s disease). Immunosuppres-
sion was achieved with the combination of cyclosporin A, mycophenolate mofetil and
methylprednisolone.
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Surgery and graft reperfusion
All grafts were retrieved from brain-dead donors and preserved with University of Wisconsin
solution at 4˚C. The surgical technique of the graft implantation and reperfusion was standard-
ized. All transplantations were performed with cross-clamping of the inferior caval vein. Neither
"piggy-back" technique nor veno-venous bypass was used. Before the anhepatic period, i.e.
clamping of hepatic artery and portal vein and native supra- and infrahepatic caval vein, all
patients were anticoagulated with 5000 IU heparin. Additional doses were given to maintain
activated clotting time (ACT) at 200–300 seconds before the anhepatic period. During graft
implantation, suprahepatic caval anastomosis was completed first. The infrahepatic caval and
portal anastomoses were then partially completed. With the suprahepatic caval vein clamped,
the graft was flushed via the portal vein first with 1000 mL of Ringer’s solution, followed by flush-
ing with approximately 400 mL of portal venous blood. Both Ringer’s solution and portal venous
blood were wasted from the infrahepatic caval anastomosis, blood constituting the graft caval
effluent. Portal and infrahepatic caval vein anastomoses were completed and the caval and portal
vein clamps were removed. Then the hepatic arterial anastomosis was completed and artery
declamped. Finally, the biliary tract was reconstructed with a Roux-en-Y hepaticojejunostomy
Surgery was performed under balanced inhalational anesthesia. Vasoactive agents used
were phenylephrine boluses and/or noradrenaline-infusion. Fluid therapy during liver trans-
plantation was left to the discretion of the attending anesthesiologist. For data analysis, we
recorded total amount and type of the fluids and blood products used during surgery.
Blood samples
During liver transplantation, systemic arterial blood samples were collected after induction of
anesthesia but before surgery (time point 1), immediately before reperfusion of the graft with
Table 1. Patient and graft characteristics.
Age (years) 49 (28–66)
Gender (male/female) 9/1
MELD-score 6 (6–13)
Child-Pugh score 5 (5–7)
Mayo risk score -0.23 (-1.45–2.09)
Cold ischemic time (hours) 4.7 (3.5–9.7)
Time from the beginning of surgery until portal vein clamping (minutes) 174 (135–209)
Anhepatic time (minutes) 51 (44–80)
Time from portal vein declamping until hepatic artery declamping
(minutes)
31 (21–47)
Perioperative bleeding (mL) 1600 (900–2600)
Graft steatosis
Grafts with any steatosis (n) 6
Macrovesicular (%) 0 (0–20)
Microvesicular (%) 0 (0–95)
Postoperative liver function
peak ALT (IU/L) 438 (213–2191)
INR on day 7 1.2 (1.0–1.3)
Bilirubin on day 7 (μmol/L) 17 (7–154)
MEAF-score 2.84 (1.38–4.81)
Data are expressed as medians (range). MELD, Model for End-stage Liver Disease; ALT, alanine aminotransferase;
INR, international normalized ratio; MEAF, Model for Early Allograft Function.
https://doi.org/10.1371/journal.pone.0221010.t001
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portal blood (time point 2), 5 minutes after portal vein declamping (time point 3), and 5 min-
utes after hepatic artery declamping (time point 4). To assess changes across the graft, blood
samples were obtained by puncture from both portal and hepatic veins at the following time
points: during reperfusion (time point 2; at this time point the sample representing hepatic
venous blood was drawn from the graft caval effluent), 5 minutes after portal vein declamping
(time point 3), and 5 minutes after hepatic artery declamping (time point 4).
The volume of each sample was 10 mL. All samples were drawn into pyrogen-free syringes
(BD Plastipak, Madrid, Spain) and then transferred into sodium citrate tubes (BD Vacutainer,
Plymouth, UK) on melting ice at 0˚C. Plasma was separated within 15 minutes by centrifuga-
tion at 2000g for 10 minutes and stored in aliquots at -80˚C until the analyses were performed.
Syndecan-1
Plasma syndecan-1 (human sCD138) levels were measured with a commercial enzyme-linked
immunosorbent (ELISA) assay (Diaclone SAS, Besancon Cedex, France). Reproducibility coef-
ficient of variation was 10.2% and assay sensitivity 4.94 ng/ml.
Heparan sulfate
Plasma heparan sulfate levels were measured with a commercial ELISA assay (Elabscience Bio-
technology Co.) for human heparan sulfate. Reproducibility coefficient of variation was <10%
and assay sensitivity 0.188 ng/ml.
Chondroitin sulfate
Plasma chondroitin sulfate levels were measured with a commercial ELISA assay (Abbexa Ltd,
Cambridge, UK) for chondroitin sulfate. Reproducibility coefficient of variation was < 10%
and assay sensitivity 0.188 ng/ml.
Clinical assessment
Plasma alanine aminotransferase (ALT), international normalized ratio (INR), and bilirubin
were measured daily as a part of the routine follow-up. For data analysis, we included the peak
ALT value measured within 7 postoperative days, and INR and bilirubin levels measured at
postoperative day 7 [15]. We also calculated the Model for Early Allograft Function (MEAF)
-score from ALT, INR and bilirubin levels [16]. Graft steatosis was assessed from routine biop-
sies taken immediately before graft perfusion during the donor operation. The graft and
patient outcome and complications within 30 days after transplantation was recorded.
Statistical analysis
All statistical analyses were performed with SPSS version 22 software package (IBM Corpora-
tion, Armonk, New York, USA). Due to the small number of patients, nonparametric tests
were used. To calculate the transhepatic gradient, portal vein value was subtracted from the
caval effluent or hepatic vein value. Unpaired data were compared with the Mann-Whitney U-
test, whereas paired data were compared with the Wilcoxon signed rank test. Time-dependent
changes were evaluated by Friedman’s test with post hoc Wilcoxon signed rank test with
Holm’s correction for multiple comparisons. Bivariate correlations were evaluated by the
Spearman rank correlation. The α-level was 0.05 for all statistical tests. Data are expressed as
medians with ranges.
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Results
Clinical outcome
Perioperative bleeding was relatively minor (Table 1). In addition to Ringer’s acetate used for
perioperative fluid therapy in all patients [5750 (range 4500–6700) mL], seven patients
received 4% albumin [800 (range 400–1400) mL] and, four patients received fresh frozen
plasma (FFP) [400 (range 400–800) mL] according to the clinical judgment of the anesthesiol-
ogist. Only one patient received packed red cells (3 units).
Five patients had significant postoperative complications. Four patients underwent relapar-
otomy, one due to biliary leakage, three due to postoperative bleeding. One of the patients
with postoperative bleeding requiring laparotomy on postoperative day 5 had undergone dial-
ysis for acute kidney injury before the bleeding. One patient had an unspecified infection,
treated with antibiotics from postoperative day 8 onwards. Despite these complications, post-
operative liver function was good in all recipients (Table 1). Both patient and graft 30-day sur-
vival were 100%. Three patients developed acute rejection, treated with steroids, during the
30-day follow-up. Despite the preoperative suspicion of cancer none of the patients had cho-
langiocarcinoma in their explanted livers. None of the explanted livers demonstrated signifi-
cant fibrosis.
Syndecan-1
Plasma syndecan-1 levels in the systemic circulation increased during surgery, significantly so
after graft reperfusion (P 0.001 Friedman’s test; Fig 1). During reperfusion, plasma syndecan-1
levels were significantly higher in the caval effluent as compared to portal venous blood, indi-
cating syndecan-1 outflow from the liver graft (Table 2, Fig 2). This syndecan-1 outflow con-
tinued at 5 min after portal vein declamping (Table 2, Fig 2).
Heparan sulfate
Plasma heparan sulfate levels in the systemic circulation decreased during surgery (P< 0.001,
Friedman’s test; Fig 1). During reperfusion, plasma heparan sulfate levels were significantly
lower in the caval effluent as compared to portal venous blood, indicating heparan sulfate
uptake within the liver graft (Table 2, Fig 2).
Chondroitin sulfate
Plasma chondroitin sulfate levels in systemic circulation decreased slightly during surgery, but
the change was statistically not significant (Fig 1). Chondroitin sulfate levels were similar in
portal blood and hepatic venous blood (Table 2, Fig 2).
Glycocalyx degradation and clinical parameters
Neither syndecan-1, heparan sulfate nor chondroitin sulfate levels correlated with graft steato-
sis, cold ischemic time, postoperative liver function or MEAF-score. Likewise, markers of gly-
cocalyx degradation did not correlate with the amount or type of fluids administered
perioperatively.
Discussion
The main finding of this study, somewhat surprisingly, is heparan sulfate sequestration within
the liver graft during reperfusion. Also, concomitant decrease in systemic heparan sulfate lev-
els occured after reperfusion. Still, this heparan sulfate uptake was accompanied by extensive
Glycocalyx degradation in LTX
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release of proteoglycan syndecan-1 from the liver graft during reperfusion, together with a
rapid increase in systemic syndecan-1 levels after reperfusion.
In accordance with our hypothesis, changes in syndecan-1 concentrations indicate that gly-
cocalyx degradation within the liver graft occurred during graft reperfusion. The results
regarding the release of syndecan-1 from the liver graft are in line with those of Snoeijs et al
[7], who demonstrated an outflow of syndecan-1 from the graft in human kidney transplanta-
tion. The marked syndecan-1 efflux from the liver graft may reflect glycocalyx degradation
occurring both during graft cold preservation and reperfusion. In experimental models of liver
IR-injury, sinusoidal endothelial cells appear particularly sensitive to cold ischemia [17] and
glycocalyx damage in the sinusoids has been described during cold preservation [18]. Thus,
the syndecan-1 efflux during reperfusion demonstrated in our patients potentially reflects a
washout of glycocalyx degradation products accumulated in the graft during cold preservation.
In addition to simple washout, the syndecan-1 efflux from the graft likely indicates exacerbated
damage to the sinusoidal endothelium during graft reperfusion. Indeed, ROS released from
sinusoidal endothelial cells, Kupffer cells and neutrophils during reperfusion [2,19] can
directly induce glycosaminoglycan fragmentation. ROS also trigger endothelial cells, leuko-
cytes and platelets to release heparanase, an enzyme degrading both heparan sulfate and synde-
can-1 [20]. Furthermore, a rapid and extensive hepatic release of MMPs and elastase occurs
during graft reperfusion in human liver transplantation [21] and these proteolytic enzymes
degrade components of glycocalyx [1,22]. In our patients, syndecan-1 release from the graft
was reflected in syndecan-1 levels in the systemic circulation, which increased significantly
after graft reperfusion, and increased continuously towards the end of the operation.
Concurrently with the increasing syndecan-1 levels in the systemic circulation, heparan sul-
fate levels decreased substantially during surgery. Our finding is surprising and contradicts the
Fig 1. Systemic concentrations of syndecan-1, heparan sulfate and chondroitin sulfate preoperatively (1), before
reperfusion (2), 5 min after portal vein declamping (3), and 5 min after hepatic artery declamping (4). Data are
depicted as median and interquartile range. �� P< 0.01 for vs preoperatively (1) and ## P< 0.01 for vs before
reperfusion (2) (Wilcoxon Signed Rank test).
https://doi.org/10.1371/journal.pone.0221010.g001
Table 2. Plasma syndecan-1, heparan sulfate and chondroitin sulfate concentrations during graft reperfusion.
Syndecan-1 (ng/ml) Heparan sulfate (ng/ml) Chondroitin sulfate ng/ml)
Reperfusion
Portal vein 101 (75–121) 112 (98–128) 12.7 (0.95–76.1)
Caval effluent 3118 (934–6141) 96 (32–129) 10.4 (0.5–73.1)
Transhepatic gradient1 3013 (814–6036)�� -15 (-81–8)� 0.5 (-11.0–3.3)
5 min after portal vein declamping
Portal vein 379 (202–830) 102 (73–126) 6.9 (0.5–40.6)
Hepatic vein 1038 (202–2207) 102 (74–128) 7.7 (0.6–44.0)
Transhepatic gradient 514 (220–1528)�� 2 (-37–26) 0.1 (-1.4–3.4)
5 min after hepatic artery declamping
Portal vein 1565 (515–3590) 36 (31–55) 8.3 (0.25–37.7)
Hepatic vein 1294 (583–3590) 30 (21–56) 7.6 (0.3–39.6)
Transhepatic gradient -165 (-2236–468) -4 (-31–23) 0.1 (-2.0–1.9)
Data are expressed as median (range).
1 [(caval effluent or hepatic vein)–(portal vein)].
� P <0.05
�� P < 0.01 (hepatic vs portal vein, Wilcoxon Signed Rank test).
https://doi.org/10.1371/journal.pone.0221010.t002
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results from previous clinical studies. In patients undergoing vascular [6] or cardiac surgery
[6,23], both biomarkers of glycocalyx degradation exhibit similar kinetics, i.e. heparan sulfate
levels increase in parallel with those of syndecan-1. Furthermore, during liver surgery with
hepatoduodenal ligament clamping, systemic heparan sulfate levels increase, although this
increase seemed to relate to surgery per se and not IR-injury [2]. In our patients, the decrease
in systemic heparan sulfate levels was marked particularly after the reperfusion of the liver
graft. Within an hour after graft reperfusion (at 5 min after hepatic artery declamping), the
median heparan sulfate level in the systemic circulation had decreased to a third as compared
to pre-reperfusion levels. Although momentary heparan sulfate sequestration within the liver,
measured as transhepatic difference in heparan sulfate levels, could be demonstrated only dur-
ing reperfusion, it seems likely that the continuously decreasing systemic heparan sulfate levels
reflected ongoing hepatic heparan sulfate uptake. Due to the surprising results in heparan sul-
fate kinetics, we measured also chondroitin sulfate levels, since it is the second most abundant
glycosaminoglycan in the glycocalyx after heparan sulfate [24]. However, neither hepatic wash-
out nor uptake of chondroitin sulfate was observed.
We can only speculate the pathophysiologic processes of hepatic heparan sulfate uptake.
We propose that heparan sulfate might be utilized in the reperfused graft in an attempt to
repair the damaged glycocalyx. Indeed, in human kidney transplantation, after the initial deg-
radation, glycocalyx thickness increased significantly within 30 min after reperfusion [7]. Like-
wise, in rodent hemorrhagic shock, volume resuscitation with fresh frozen plasma, but not
with lactated Ringer’s solution, restored glycocalyx within two hours [25,26]. These in vivo
results indicate that damaged glycocalyx may be repaired very rapidly (within the sampling
time range of the present study) through endogenous processes. Furthermore, in experimental
models with chemical glycocalyx degradation, intravascular administration of exogenous
heparan sulfate restores glycocalyx [27,28]. Because we did not take graft biopsies nor intravital
microscopy for direct evaluation of glycocalyx thickness graft heparan sulfate uptake as a
reflection of acute glycocalyx reparation remains speculative to this date.
In our highly selected patient cohort, either syndecan-1 release, that reflects damaged glyco-
calyx, or potential reparative heparan sulfate uptake, did not translate into clinical outcomes.
However, preventing glycocalyx degradation during graft preservation and reperfusion could
offer a strategy to improve clinical outcomes in liver transplantation, especially with regard to
marginal grafts. The seemingly most feasible method for protecting graft glycocalyx during
preservation is to supplement the preservation solution with substances known to inhibit gly-
cocalyx degradation under inflammatory conditions, for example steroids [29–31], serine pro-
tease inhibitors antithrombin [32] and tranexamic acid [33,34], heparin and heparinoids
[28,35,36] or sphingosine-1-phospate [28,37]. None of the current commercially available
preservation solutions contain these substances [38]. Where machine perfusion is available,
replacing gelatin [39] with albumin or FFP [25,26,40], or supplementing the perfusion solution
with any one of the above-mentioned substances might be feasible. Alternatively, glycocalyx
degradation might be alleviated by graft flushing with FFP or albumin [25,26,40] immediately
prior to reperfusion.
Our study has several strenghts. First, the surgeons took the blood samples by direct needle
puncture from the portal and hepatic veins. Thus, the obtained results reflect real concentra-
tion differences across the reperfused liver. Second, our study cohort was homogenous. As
Fig 2. Transhepatic gradients [(caval effluent or hepatic vein)–(portal vein)] of syndecan-1, heparan sulfate and
chondroitin sulfate at reperfusion (2), 5 minutes after portal vein declamping (3) and 5 minutes after hepatic
artery declamping (4). � P< 0.05 and �� P< 0.01 for hepatic vs portal vein (Wilcoxon Signed Rank test).
https://doi.org/10.1371/journal.pone.0221010.g002
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patients with chronic liver disease have elevated syndecan-1 [10] and heparan sulfate [12] lev-
els, we chose to eliminate this confounding factor by enrolling a homogenous group of patients
undergoing liver transplantation for PSC with premalignant biliary lesions [13,14] and thus
having normal preoperative liver function. The chosen patient selection was reflected in the
low preoperative (MELD) score of median 6.
There are limitations to this study. First, given the small number of highly selected patients
and non-steatotic grafts with short cold ischemic times, and thus excellent postoperative liver
function with a median MEAF-score of 2.84 [16], the lacking correlations between syndecan-
1, heparan sulfate or chondroitin sulfate levels during reperfusion and the subsequent liver
function are not surprising. Thus, our findings cannot be generalized into cirrhotic patients or
marginal grafts. Second, seven of the ten patients had inflammatory bowel disease, which may
have slightly increased the baseline syndecan-1 levels [41]. Third, the levels of glycocalyx deg-
radation makers might have been affected by the unstandardized fluid therapy during trans-
plantation. Indeed, the administration of albumin in seven patients and FFP in four patients
might have affected syndecan-1 levels (25,26,39). Fourth, during the anhepatic period, all
patients were anticoagulated with heparin and received a standard dose of methylprednisolone
prior to graft reperfusion, both of which may alleviate glycocalyx degradation [29,30,35] and
thus might potentially have affected syndecan-1, heparan sulfate and chondroitin sulfate levels
in our patients.
Taken together, we demonstrated graft glycocalyx degradation during reperfusion in
human liver transplantation in a selected patient cohort with normal liver and hemostatic
function. The extensive syndecan-1 release from the graft was associated with concomitant
heparan sulfate uptake into the graft, suggesting heparan sulfate can be utilized within the graft
in pathophysiologic processes. To the best of our knowledge, this is the first in vivo observation
of endogenous heparan sulfate uptake in a clinical context. In the light of previous experimen-
tal [25–28] and clinical [7] literature, we speculate that graft heparan sulfate uptake in our
study might reflect endogenous reparative processes to mend the damaged glycocalyx. Our
findings call for both experimental and clinical studies to delineate the actual mechanisms of
glycocalyx degradation and reparation in cold ischemic IR-injury. Likewise, future studies in
larger patient cohorts are needed to explore the clinical significance of graft glycocalyx degra-
dation in human liver transplantation.
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